# US 2012/0252123 A1 · Nucleic acid silencing sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252123 A1
- Document ID: US20120252123A1
- Status: Published application
- Kind: A1
- Application number: 13/483,240
- Filed: 2012-05-30
- Published: 2012-10-04
- Earliest claimed: 2008-07-30
- Assignees: University of Massachusetts
- Inventors: Jeanne B. Lawrence; Lisa L. Hall
- Web page: https://patentgrep.com/patent/US20120252123A1

## CPC

- C12N 15/85: for animal cells
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C12N 2310/11: Antisense
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/10: naturally occurring
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention features compositions and methods for introducing, into cells, nucleic acids whose expression results in chromosomal silencing. The nucleic acids are targeted to specific chromosomal regions where they subsequently reduce the expression of deleterious genes, or cause the death of deleterious cells. Where the nucleic acid sequence is a silencing sequence, it may encode an Xist RNA or other non-coding, silencing RNA. Accordingly, the present invention features, inter alia, nucleic acid constructs that include a transgene (e.g., a silencing sequence encoding an Xist RNA or other non-coding RNA that silences a segment of a chromosome); first and second sequences that direct insertion of the silencing sequence into a targeted chromosome; and, optionally, a selectable marker.

## Claims

### Claim 1

A composition comprising:
a vector comprising a nucleic acid construct comprising:
a silencing sequence encoding an Xist RNA; and
first and second sequences homologous to a site of desired integration in human chromosome 13, 18, or 21 or mouse chromosome 16 that specifically direct insertion of the silencing sequence into human chromosome 13, 18, or 21 or mouse chromosome 16 by homologous recombination.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the silencing sequence is a full-length Xist gene sequence.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the silencing sequence is an Xist gene sequence exclusive of one or more introns.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the silencing sequence comprises about 6 kb to about 10 kb of exon 1 of an Xist gene sequence.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the silencing sequence comprises the Xist cDNA sequence having accession number M97168 or a biologically active fragment or other variant thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the silencing sequence comprises a biologically active fragment or other biologically active variant of a naturally occurring Xist gene sequence.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a regulatory sequence.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the regulatory sequence is a constitutively active, inducible, tissue-specific, or developmental stage-specific promoter.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the first and second sequences direct insertion of the silencing sequence into a polymorphic region of the targeted chromosome.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the first and second sequences direct insertion of the silencing sequence into an APP gene.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the vector comprising the nucleic acid construct further comprises a selectable marker.

### Claim 12 (depends on 1)

An isolated trisomic cell comprising the composition of claim 1.

### Claim 13 (depends on 12)

The isolated trisomic cell of claim 12, wherein the cell is a somatic cell or a stem cell.

### Claim 14 (depends on 1)

An isolated cell comprising the composition of claim 1.

### Claim 15 (depends on 14)

The isolated cell of claim 14, wherein the cell is a germ cell, a stem cell, or a precursor cell.

### Claim 16 (depends on 15)

The isolated cell of claim 15, wherein the stem cell is an embryonic stem cell, an adult stem cell, or an induced pluripotent stem cell.

### Claim 17 (depends on 16)

The isolated cell of claim 16, wherein the adult stem cell is a hematopoietic stem cell or a neural stem cell.

### Claim 18 (depends on 14)

The isolated cell of claim 14, wherein the cell is a differentiated cell.

### Claim 19 (depends on 18)

The isolated cell of claim 18, wherein the differentiated cell is a fibroblast or neuron.

### Claim 20

A method of reducing gene expression from a trisomic human chromosome 13, 18, or 21 or mouse chromosome 16 in a cell, the method comprising:
providing a cell comprising a trisomic human chromosome 13, 18, or 21 or mouse chromosome 16; and introducing into the cell a vector comprising a nucleic acid construct comprising:
a silencing sequence encoding an Xist RNA; and
first and second sequences homologous to a site of desired integration in human chromosome 13, 18, or 21 or mouse chromosome 16 that specifically direct insertion of the silencing sequence into human chromosome 13, 18, or 21 or mouse chromosome 16 by homologous recombination.
